Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom MacLeod

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Scientific Reports|April 23, 2016
Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonistTom Macleod, Rosella Doble, Dennis McGonagle, et al.
RMD Open|May 25, 2024
Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjectsPaula David, Or Hen, Niv Ben-Shabbat, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 19, 2024
Epidermal proteomics demonstrates Elafin as a psoriasis-specific biomarker and highlights increased anti-inflammatory activity around psoriatic plaquesAnna Berekmeri, Tom Macleod, Isabel Hyde, et al.
RMD Open|December 19, 2023
Anti-IL-5 biologics and rheumatoid arthritis: a single-centre 500 patient year exposure analysisNathan J Dean, Ian J Clifton, Rashad Salman, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2017
Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γJoseph S Ainscough, Tom Macleod, Dennis McGonagle, et al.
Frontiers in Immunology|March 15, 2018
IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates AngiogenesisCharlie Bridgewood, Gareth W Fearnley, Anna Berekmeri, et al.
The Journal of Investigative Dermatology|April 8, 2022
T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune DiseasesCharlie Bridgewood, Miriam Wittmann, Tom Macleod, et al.
Frontiers in Immunology|December 1, 2025
Human spinal enthesis comparative biology of IL-17F and IL-17A reveals greater T-cell IL-17F induction and IL-23 regulationNicole McDermott, Ala Altaie, Tom Macleod, et al.
Journal of Autoimmunity|June 17, 2026
Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibitionAntonio Tonutti, Vlad Voiculescu, Francesca Trunfio, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 22, 2025
Late-Onset Spondylarthritis Presenting as Glucocorticoid-Resistant Polymyalgia Rheumatica: A hitherto underappreciated entity where TNF or IL-17 Blockade may have a Therapeutic RoleKerem Abacar, Gabriele De Marco, Jake Weddell, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Scientific Reports|April 23, 2016
Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonistTom Macleod, Rosella Doble, Dennis McGonagle, et al.
RMD Open|May 25, 2024
Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjectsPaula David, Or Hen, Niv Ben-Shabbat, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 19, 2024
Epidermal proteomics demonstrates Elafin as a psoriasis-specific biomarker and highlights increased anti-inflammatory activity around psoriatic plaquesAnna Berekmeri, Tom Macleod, Isabel Hyde, et al.
RMD Open|December 19, 2023
Anti-IL-5 biologics and rheumatoid arthritis: a single-centre 500 patient year exposure analysisNathan J Dean, Ian J Clifton, Rashad Salman, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2017
Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γJoseph S Ainscough, Tom Macleod, Dennis McGonagle, et al.
Frontiers in Immunology|March 15, 2018
IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates AngiogenesisCharlie Bridgewood, Gareth W Fearnley, Anna Berekmeri, et al.
The Journal of Investigative Dermatology|April 8, 2022
T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune DiseasesCharlie Bridgewood, Miriam Wittmann, Tom Macleod, et al.
Frontiers in Immunology|December 1, 2025
Human spinal enthesis comparative biology of IL-17F and IL-17A reveals greater T-cell IL-17F induction and IL-23 regulationNicole McDermott, Ala Altaie, Tom Macleod, et al.
Journal of Autoimmunity|June 17, 2026
Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibitionAntonio Tonutti, Vlad Voiculescu, Francesca Trunfio, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 22, 2025
Late-Onset Spondylarthritis Presenting as Glucocorticoid-Resistant Polymyalgia Rheumatica: A hitherto underappreciated entity where TNF or IL-17 Blockade may have a Therapeutic RoleKerem Abacar, Gabriele De Marco, Jake Weddell, et al.
Pageof 3